Background and ObjectivesAntibodies to proteolipid protein-1 (PLP1-IgG), a major central myelin protein also expressed in the peripheral nervous system (PNS) as the isoform DM20, have been previously identified mostly in patients with multiple sclerosis (MS), with unclear clinical implications. However, most studies relied on nonconformational immunoassays and included few patients with non-MS CNS autoimmune demyelinating disorders (ADDs). We aimed to investigate conformational PLP1-IgG in the whole ADD spectrum. METHODS We devised a new live cell-based assay (CBA) for PLP1-IgG and used it to test 2 cohorts (retrospective exploratory, n = 284; prospective validation, n = 824) of patients with ADDs and controls (n = 177). Patients were classified as MS, neuromyelitis optica spectrum disorders (NMOSDs), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), and other ADDs. PLP1-IgG-positive samples were tested for IgG subclasses, DM20-IgG, and on rat brain tissue-based ...
Conformational Antibodies to Proteolipid Protein-1 and Its Peripheral Isoform DM20 in Patients With CNS Autoimmune Demyelinating Disorders / Masciocchi, S.; Businaro, P.; Greco, G.; Scaranzin, S.; Malvaso, A.; Morandi, C.; Zardini, E.; Risi, M.; Vegezzi, E.; Diamanti, L.; Bini, P.; Siquilini, S.; Giannoccaro, M. P.; Morelli, L.; Liguori, R.; Patti, F.; De Giuli, V.; Portaccio, E.; Zanetta, C.; Bergamoni, S.; Simone, A. M.; Lanzillo, R.; Bruno, G.; Gallo, A.; Bisecco, A.; Di Filippo, M.; Pauri, F.; Toriello, A.; Barone, P.; Tazza, F.; Bucello, S.; Banfi, P.; Fabris, M.; Volonghi, I.; Raciti, L.; Vigliani, M. C.; Bocci, T.; Paoletti, M.; Colombo, E.; Filippi, M.; Pichiecchio, A.; Marchioni, E.; Franciotta, D.; Gastaldi, M.. - In: NEUROLOGY® NEUROIMMUNOLOGY & NEUROINFLAMMATION. - ISSN 2332-7812. - 12:2(2025). [10.1212/NXI.0000000000200359]
Conformational Antibodies to Proteolipid Protein-1 and Its Peripheral Isoform DM20 in Patients With CNS Autoimmune Demyelinating Disorders
Di Filippo M.;Fabris M.;Colombo E.;Filippi M.;
2025-01-01
Abstract
Background and ObjectivesAntibodies to proteolipid protein-1 (PLP1-IgG), a major central myelin protein also expressed in the peripheral nervous system (PNS) as the isoform DM20, have been previously identified mostly in patients with multiple sclerosis (MS), with unclear clinical implications. However, most studies relied on nonconformational immunoassays and included few patients with non-MS CNS autoimmune demyelinating disorders (ADDs). We aimed to investigate conformational PLP1-IgG in the whole ADD spectrum. METHODS We devised a new live cell-based assay (CBA) for PLP1-IgG and used it to test 2 cohorts (retrospective exploratory, n = 284; prospective validation, n = 824) of patients with ADDs and controls (n = 177). Patients were classified as MS, neuromyelitis optica spectrum disorders (NMOSDs), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), and other ADDs. PLP1-IgG-positive samples were tested for IgG subclasses, DM20-IgG, and on rat brain tissue-based ...| File | Dimensione | Formato | |
|---|---|---|---|
|
Neurol Neuroimmunol Neuroinflamm 12_e200359.pdf
accesso aperto
Tipologia:
PDF editoriale (versione pubblicata dall'editore)
Licenza:
Creative commons
Dimensione
1.33 MB
Formato
Adobe PDF
|
1.33 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.


